250 related articles for article (PubMed ID: 30024293)
1. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
[TBL] [Abstract][Full Text] [Related]
2. Immune Mechanisms in Myelodysplastic Syndrome.
Glenthøj A; Ørskov AD; Hansen JW; Hadrup SR; O'Connell C; Grønbæk K
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314337
[TBL] [Abstract][Full Text] [Related]
3. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
[TBL] [Abstract][Full Text] [Related]
4. [Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes].
Nakajima H
Rinsho Ketsueki; 2023; 64(8):753-763. PubMed ID: 37673628
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
6. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
Sallman DA; Tanaka TN; List A; Bejar R
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):613-620. PubMed ID: 29025689
[TBL] [Abstract][Full Text] [Related]
7. Emerging immunosuppressive drugs in myelodysplastic syndromes.
Epling-Burnette PK; McDaniel J; Wei S; List AF
Expert Opin Emerg Drugs; 2012 Dec; 17(4):519-41. PubMed ID: 23163589
[TBL] [Abstract][Full Text] [Related]
8. The current perspective of low-grade myelodysplastic syndrome in children.
Hasegawa D
Int J Hematol; 2016 Apr; 103(4):360-4. PubMed ID: 26939774
[TBL] [Abstract][Full Text] [Related]
9. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
Warlick ED; Miller JS
Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
[TBL] [Abstract][Full Text] [Related]
11. Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
Ivy KS; Brent Ferrell P
Curr Hematol Malig Rep; 2018 Aug; 13(4):244-255. PubMed ID: 29934935
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy for myelodysplastic syndromes: refining the indications.
Barrett AJ; Sloand EM
Curr Hematol Malig Rep; 2008 Jan; 3(1):23-8. PubMed ID: 20425443
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in the treatment of myelodysplastic syndromes].
Gelsi-Boyer V; Vey N
Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
[TBL] [Abstract][Full Text] [Related]
14. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
[TBL] [Abstract][Full Text] [Related]
15. Immunologic aspects of hypoplastic myelodysplastic syndrome.
Calado RT
Semin Oncol; 2011 Oct; 38(5):667-72. PubMed ID: 21943673
[TBL] [Abstract][Full Text] [Related]
16. The genetic and molecular pathogenesis of myelodysplastic syndromes.
Shallis RM; Ahmad R; Zeidan AM
Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
[TBL] [Abstract][Full Text] [Related]
17. The role of the immune system in myelodysplasia: implications for therapy.
Sloand EM; Rezvani K
Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
[TBL] [Abstract][Full Text] [Related]
18. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes.
Greenberg PL; Young NS; Gattermann N
Hematology Am Soc Hematol Educ Program; 2002; ():136-61. PubMed ID: 12446422
[TBL] [Abstract][Full Text] [Related]
20. Chronic immune response dysregulation in MDS pathogenesis.
Barreyro L; Chlon TM; Starczynowski DT
Blood; 2018 Oct; 132(15):1553-1560. PubMed ID: 30104218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
